(Q24246033)

5

0 references

Andrea Cipriani

4

0 references

Rachel Churchill

7

0 references

Hugh McGuire

6

Hugh McGuire

0 references

Atsuo Nakagawa

Atsuo Nakagawa

1

1 reference

ORCID Public Data File 2021

Rachel Churchill

1 reference

ORCID Public Data File 2021

Toshi A Furukawa

8

Toshi A Furukawa

0 references

Ichiro M Omori

3

Ichiro Omori

0 references

Norio Watanabe

2

Cochrane Database of Systematic Reviews

Norio Watanabe

0 references

publication date

18 April 2007

0 references

published in

0 references

cites work

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

"Wish bias" in antidepressant drug trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Industry sponsorship and authorship of clinical trials over 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Are we going to increase the use of antidepressants up to that of benzodiazepines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Prevalence, nature, and comorbidity of depressive disorders in primary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

The economic burden of depression in the US: societal and patient perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Amitriptyline versus other types of pharmacotherapy for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

A comparative study of milnacipran and imipramine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

A consumer's guide to subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

A comparative study of milnacipran and paroxetine in outpatients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Milnacipran. A review of its use in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

A systematic review of newer pharmacotherapies for depression in adults: evidence report summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Preclinical pharmacology of milnacipran

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Imputing response rates from means and standard deviations in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

7 January 2021

Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

7 January 2021

A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

7 January 2021

Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

7 January 2021

Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

7 January 2021

Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

7 January 2021

Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529

7 January 2021